Eikon Therapeutics EIKN Institutional Ownership

Updated Oct 10, 2026

Eikon Therapeutics, Inc. (NASDAQ:EIKN) had 77 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Their combined stake equaled 48.94% of outstanding shares in Q2 2026, up from 43.86% in Q1 2026.
• Total holdings of EIKN shares rose 11.62% from Q1 2026.
• Among the 77 holders of Eikon Therapeutics, 54 added to their positions, 9 reduced their stakes and 14 left their positions unchanged.
• The aggregate institutional position in Eikon Therapeutics was 26.5Mn shares at the end of Q2 2026, up 2.76Mn from the prior quarter.
• FMR LLC was the top holder of Eikon Therapeutics as of June 30, 2026, with 4.99Mn shares, or 9.22% of shares outstanding.
• Among holders that already owned Eikon Therapeutics, the biggest buyers in Q2 2026 were FMR LLC (+1.16Mn shares), BlackRock, Inc. (+962.05K shares), T. Rowe Price Investment Management, Inc. (+372.79K shares), State Street Corp (+313.94K shares) and Geode Capital Management, LLC (+283.02K shares).
• Holders that trimmed the most shares of Eikon Therapeutics in Q2 2026 while keeping a position were AllianceBernstein L.P. (-380.3K shares), Citadel Advisors LLC (-296.98K shares), Bank of America Corp (-48.56K shares), Vanguard Capital Management LLC (-46.72K shares) and Millennium Management LLC (-42.61K shares).
• Business Quant data shows the 10 biggest positions in Eikon Therapeutics as of Q2 2026 were held by FMR LLC (4.99Mn shares), BlackRock, Inc. (4.28Mn shares), Foresite Capital Management IV, LLC (1.94Mn shares), Merck & Co., Inc. (1.67Mn shares), T. Rowe Price Investment Management, Inc. (1.6Mn shares), Foresite Capital Management V, LLC (1.32Mn shares), Capital World Investors (1.18Mn shares), T. Rowe Price Associates Inc (1.01Mn shares), Vanguard Capital Management LLC (922.71K shares) and EcoR1 Capital, LLC (732.61K shares).